Clinical Trials
19 trialsNCT04865679 2026-06-03
REPOSE-XLâ„
Axogen Corporation
Phase NA Active not recruiting
NCT07484022 2026-06-03
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT06848348 2026-05-29
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Dogwood Therapeutics Inc.
Phase 2 Recruiting
NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT05488873 2024-07-22
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
WinSanTor, Inc
Phase 2 Active not recruiting
NCT04287075 2024-03-26
Rethink Pain
Axogen Corporation
Terminated
NCT04675450 2023-06-08
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Conjupro Biotherapeutics, Inc.
Phase 2 Withdrawn
NCT03027245 2022-07-13
IRENE
Eisai Inc.
Completed
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT04034355 2022-01-26
POLAR-A
Egetis Therapeutics
Phase 3 Terminated
NCT03065478 2018-09-06
STEFANO
Swiss Medical Food AG
Completed
NCT01689610 2018-06-20
NABUCCO
iOMEDICO AG
Completed
NCT01697839 2018-03-05
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
Oncotherapeutics
Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed
NCT00267007 2014-06-04
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00380965 2008-02-15
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
NEMA Research, Inc.
Phase 4 Completed
NCT00041795 2005-06-24
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
NeoTherapeutics
Phase 2 Completed